145 related articles for article (PubMed ID: 35994576)
1. U.S. Women Need the Dapivirine Ring, Too: FDA as Structural Barrier to HIV Prevention for Women.
Gollub EL; Vaughan R
AIDS Educ Prev; 2022 Aug; 34(4):311-324. PubMed ID: 35994576
[TBL] [Abstract][Full Text] [Related]
2. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
[TBL] [Abstract][Full Text] [Related]
3. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
Baeten JM; Palanee-Phillips T; Mgodi NM; Mayo AJ; Szydlo DW; Ramjee G; Gati Mirembe B; Mhlanga F; Hunidzarira P; Mansoor LE; Siva S; Govender V; Makanani B; Naidoo L; Singh N; Nair G; Chinula L; Parikh UM; Mellors JW; Balán IC; Ngure K; van der Straten A; Scheckter R; Garcia M; Peda M; Patterson K; Livant E; Bunge K; Singh D; Jacobson C; Jiao Y; Hendrix CW; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Torjesen K; Nel A; Rosenberg Z; Soto-Torres LE; Hillier SL; Brown ER;
Lancet HIV; 2021 Feb; 8(2):e87-e95. PubMed ID: 33539762
[TBL] [Abstract][Full Text] [Related]
4. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
[TBL] [Abstract][Full Text] [Related]
5. Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.
Roberts ST; Nair G; Baeten JM; Palanee-Philips T; Schwartz K; Reddy K; Kabwigu S; Matovu Kiweewa F; Govender V; Gaffoor Z; Singh N; Siva S; Naidoo K; Montgomery ET;
AIDS Behav; 2020 May; 24(5):1432-1442. PubMed ID: 31667678
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.
Murphy DJ; Desjardins D; Dereuddre-Bosquet N; Brochard P; Perrot L; Pruvost A; Le Grand R; Lagatie O; Vanhooren L; Feyaerts M; van Roey J; Malcolm RK
J Antimicrob Chemother; 2014 Sep; 69(9):2477-88. PubMed ID: 24862093
[TBL] [Abstract][Full Text] [Related]
7. Adolescent Girls and Young Women's Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: a Multi-Country Qualitative Analysis.
Young AM; Mancuso N; Atujuna M; Tenza S; Chitukuta M; Kemigisha D; Ngure K; van der Straten A; Garcia M; Szydlo D; Soto-Torres L; Roberts ST
AIDS Behav; 2023 Dec; 27(12):3941-3951. PubMed ID: 37392268
[TBL] [Abstract][Full Text] [Related]
8. Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.
Husnik MJ; Brown ER; Dadabhai SS; Gaffoor Z; Jeenarain N; Kiweewa FM; Livant E; Mansoor LE; Mirembe BG; Palanee-Phillips T; Singh D; Siva S; Soto-Torres L; van der Straten A; Baeten JM;
AIDS Behav; 2021 Sep; 25(9):2801-2814. PubMed ID: 34117592
[TBL] [Abstract][Full Text] [Related]
9. Development of dapivirine vaginal ring for HIV prevention.
Devlin B; Nuttall J; Wilder S; Woodsong C; Rosenberg Z
Antiviral Res; 2013 Dec; 100 Suppl():S3-8. PubMed ID: 24188702
[TBL] [Abstract][Full Text] [Related]
10. Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES.
McBride JW; Malcolm RK; Dias N; Cameron D; Offord RE; Hartley O; Kett VL; Devlin B; Boyd P
Int J Pharm; 2019 Jun; 564():207-213. PubMed ID: 30999049
[TBL] [Abstract][Full Text] [Related]
11. Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?
Bhavaraju N; Shears K; Schwartz K; Mullick S; Jeckonia P; Murungu J; Persaud U; Vij A; Torjesen K
Curr HIV/AIDS Rep; 2021 Dec; 18(6):508-517. PubMed ID: 34910276
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
[TBL] [Abstract][Full Text] [Related]
13. Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial.
Mirembe BG; Cabrera MV; van der Straten A; Nakalega R; Cobbing M; Mgodi NM; Palanee-Phillips T; Mayo AJ; Dadabhai S; Mansoor LE; Siva S; Nair G; Chinula L; Akello CA; Nakabiito C; Soto-Torres LE; Baeten JM; Brown ER
AIDS Behav; 2023 Mar; 27(3):1030-1043. PubMed ID: 36066762
[TBL] [Abstract][Full Text] [Related]
14. Impact of Women's Home Environment on Use of the Dapivirine Vaginal Ring for HIV Prevention in Sub-Saharan Africa.
Gichane MW; Katz AWK; Ngure K; Scheckter R; Woeber K; Reddy K; Tauya T; Zimba C; Etima J; Mangxilana N; Palanee-Phillips T; van der Straten A;
AIDS Behav; 2021 Dec; 25(12):3847-3857. PubMed ID: 34009480
[TBL] [Abstract][Full Text] [Related]
15. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.
Nel A; Bekker LG; Bukusi E; Hellstrӧm E; Kotze P; Louw C; Martinson F; Masenga G; Montgomery E; Ndaba N; van der Straten A; van Niekerk N; Woodsong C
PLoS One; 2016; 11(3):e0147743. PubMed ID: 26963505
[TBL] [Abstract][Full Text] [Related]
16. Ring-ing in the Future: Participant and Male Partner Perspectives Regarding Future Use of the Dapivirine Vaginal Ring for HIV Prevention.
Reddy K; Mathebula F; Katz A; Luecke E; Tenza S; Palanee-Phillips T; Garcia M; Mansoor LE; Naidoo S; Morar N; Chitukuta M; Tsidya M; Montgomery ET;
AIDS Behav; 2022 Jun; 26(6):1923-1932. PubMed ID: 35064389
[TBL] [Abstract][Full Text] [Related]
17. HIV prevention at drug shops: awareness and attitudes among shop dispensers and young women about oral pre-exposure prophylaxis and the dapivirine ring in Shinyanga, Tanzania.
Tubert J; Packel L; Hunter LA; Mfaume R; Njau P; Ramadhani AA; Liu JX; McCoy SI
AIDS Res Ther; 2021 Apr; 18(1):21. PubMed ID: 33902623
[TBL] [Abstract][Full Text] [Related]
18. Using Emoji Stickers to Understand End-User Opinions of the Dapivirine Vaginal Ring for HIV Prevention.
Katz AWK; Mansoor LE; Tsidya M; Mathebula F; Singh D; Siva S; Akello C; Chitowa TH; Garcia M; Soto-Torres L; Montgomery ET
AIDS Behav; 2021 Dec; 25(12):3955-3966. PubMed ID: 34180041
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.
Riddler SA; Balkus JE; Parikh UM; Mellors JW; Akello C; Dadabhai S; Mhlanga F; Ramjee G; Mayo AJ; Livant E; Heaps AL; O'Rourke C; Baeten JM;
Clin Infect Dis; 2019 Jul; 69(3):523-529. PubMed ID: 30346511
[TBL] [Abstract][Full Text] [Related]
20. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
Nel A; van Niekerk N; Van Baelen B; Malherbe M; Mans W; Carter A; Steytler J; van der Ryst E; Craig C; Louw C; Gwetu T; Mabude Z; Kotze P; Moraba R; Tempelman H; Gill K; Kusemererwa S; Bekker LG; Devlin B; Rosenberg Z;
Lancet HIV; 2021 Feb; 8(2):e77-e86. PubMed ID: 33539761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]